Everything below concerns visceral adipose tissue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-30. Numbers and descriptions here follow the published literature rather than marketing material.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
== Uses == Oclacitinib is labeled to treat atopic dermatitis and itchiness (pruritus) caused by allergies in dogs, though it has also been used to reduce the itchiness and dermatitis caused by flea infestations. While some say it is best only for acute flares of itchiness, others claim that it is also useful in chronic atopic dermatitis. It is considered to be highly effective in dogs and has been established as safe for at least short-term use. Its efficacy is comparable to prednisolone early in treatment, and although oclacitinib has been shown to be more effective in the short term for itchiness and dermatitis, its long-term safety is incompletely established. It has been found to have a faster onset and cause less gastrointestinal issues than cyclosporine. There is some off-label use of oclacitinib to treat asthma and allergic dermatitis in cats, but its efficacy has not been established.
Food and Drug Administration concluded that TDA-induced breast cancer was an infinitesimal health-risk to women with breast implants, and did not justify legally requiring physicians to explain the matter to their patients. In the event, polyurethane-coated breast implants remain in plastic surgery practice in Europe and in South America; and no manufacturer has sought FDA approval for medical sales of such breast implants in the U.S.
== Release == Stargirl premiered on DC Universe on May 18, 2020, with the first season consisting of 13 episodes. The series was originally intended to premiere on May 11, seven days before its official release. The series was released in 4K Ultra HD on DC Universe. In November 2019, The CW announced to broadcast each episode the day after it premieres on the streaming service, with each episode available to stream on The CW's online platforms after its broadcast. Stargirl started airing on The CW on May 19, 2020, at 8 pm. Some episodes have content removed when they air on The CW to allow for the network's commercials, notably approximately eight minutes in each of the first two episodes. DC Universe streamed the full episodes, and Johns said starting with the third episode, both releases are "almost identical". The series release plans shifted and it stayed in post-production longer to accommodate the broadcast on The CW to accomplish the adjustments that had to be made. Scenes removed in the first episode from The CW broadcast included: establishing shots of Barbara Whitmore's new job, and Pat's auto shop; an interaction between Courtney and Cindy Burman in the halls of Blue Valley High School that Alex Zalben of Decider said was "clear set-up for later" but helped strengthen Courtney's emotional arc; and Mark Ashworth's scenes as "a mysterious, extremely creepy bearded janitor", which Zalben said was more of "a fun Easter egg that will pay dividends down the road"; and Courtney finding a newspaper article about Starman and Stripesy.
== Early life == Born in Boston, Massachusetts, as the only son of Janice (née Hare) and Robert Bagwell, Jeff Bagwell and his family moved to Killingworth, Connecticut, when he was one year old. Much of Bagwell's family is from the Greater Boston area, including both his parents, and are avid fans of the Boston Red Sox. His favorite baseball player, Carl Yastrzemski, was a longtime left fielder for the Red Sox. Robert, from Watertown, pitched college baseball at Northeastern University and as a semi-professional. Janice, a police officer, grew up in Newton and played softball in local Boston leagues until her 20s. Bagwell's parents divorced when he was 11. Precocious and demonstrating much athletic ability early in life, he played a wide variety of sports as a youth. Recalled Janice, Jeff "could throw a ball before he could walk. When he was six months old, we'd throw a ball to him and he would throw it back." Bagwell graduated from Xavier High School, a private all-male Catholic school located in Middletown, Connecticut. A versatile athlete, he excelled at soccer, setting the school goal-scoring mark, played shortstop, and lettered in basketball. In early 1989, Bagwell was honored by Xavier for his character and generosity. He also excelled in American Legion Baseball under coach Fred Tremalgia for Post 75 in Middletown and went on to be named the 2003 American Legion Baseball Graduate of the Year.
Sources: en.wikipedia.org
== Biosynthesis and secretion == The FNDC5 gene encodes a prohormone, a single-pass type I membrane protein (human, 212 amino acids; mouse and rat, 209 amino acids) that is upregulated by muscular exercise and undergoes post-translational processing to generate irisin. The sequence of the protein includes a signal peptide, a single fibronectin type III domain, and a C-terminal hydrophobic domain that is anchored in the cell membrane. The production of irisin is similar to the shedding and release of other hormones and hormone-like polypeptides, such as epidermal growth factor and TGF alpha, from transmembrane precursors. After the N-terminal signal peptide is removed, the peptide is proteolytically cleaved from the C-terminal moiety, glycosylated and released as a hormone of 112 amino acids (in human, amino acids 32–143 of the full-length protein; in mouse and rat, amino acids 29–140) that comprises most of the FNIII repeat region. The protease/enzyme responsible for the cleavage of FNDC5 to its secreted form, irisin, has not been identified. The sequence of irisin is highly conserved in mammals; the human and murine sequences are identical. However, the start codon of human FNDC5 is mutated to ATA. This causes human FNDC5 to be potentially expressed in two versions:
In early 1954, he wrote the article "Cobalt 60 – Danger or Blessing for Mankind?", about the misuse of atomic energy, which was widely reprinted and transmitted in the radio in Germany, Norway, Austria, and Denmark, and in an English version worldwide via the BBC. The international reaction was encouraging. The following year he initiated and organised the Mainau Declaration of 1955, in which he and other international Nobel Prize-winners called attention to the dangers of atomic weapons and urgently warned the nations of the world against the use of "force as a final resort", and which was issued a week after the similar Russell-Einstein Manifesto. In 1956, Hahn repeated his appeal with the signature of 52 of his Nobel colleagues from all parts of the world. Hahn was also instrumental in and one of the authors of the Göttingen Manifesto of 13 April 1957, in which, together with 17 leading German atomic scientists, he protested against a proposed nuclear arming of the West German armed forces (Bundeswehr). This resulted in Hahn receiving an invitation to meet the Chancellor of Germany, Konrad Adenauer and other senior officials, including the Defense Minister, Franz Josef Strauss, and Generals Hans Speidel and Adolf Heusinger (who had both been generals in the Nazi era). The two generals argued that the Bundeswehr needed nuclear weapons, and Adenauer accepted their advice. A communiqué was drafted that said that the Federal Republic did not manufacture nuclear weapons, and would not ask its scientists to do so.
To claim this reward, a special transaction called a coinbase is included in the block, with the miner as the payee. All bitcoins in existence have been created through this type of transaction. This reward is halved every 210,000 blocks until ₿21 million have been issued in total, which is expected to occur around the year 2140. Afterward, miners will only earn from transaction fees. These fees are determined by the transaction's size and the amount of data stored, measured in satoshis per byte. The proof of work system and the chaining of blocks make blockchain modifications very difficult, as altering one block requires changing all subsequent blocks. As more blocks are added, modifying older blocks becomes increasingly challenging. In case of disagreement, nodes trust the longest chain, which required the greatest amount of effort to produce. To tamper or censor the ledger, one needs to control the majority of the global hashrate. The high cost required to reach this level of computational power secures the bitcoin blockchain. The environmental impact of bitcoin mining is controversial and has attracted the attention of regulators, leading to restrictions or incentives in various jurisdictions. As of 2025, a non-peer-reviewed study by the Cambridge Centre for Alternative Finance (CCAF) estimated that bitcoin mining represented 0.5% of global electricity consumption and 0.08% of world greenhouse gas emissions, comparable to Slovakia's emissions. About half of the electricity used is generated through fossil fuels.
John Martin Shaw, Director of Planning and Transportation, Norfolk County Council. For services to Local Government. William Francis Sheridan, Head of International Policy, Forestry Commission. Francis Edward Shields, , lately Chief Executive, National Federation of Young Farmers' Clubs. For services to the Young Farmers Club Movement. Ian Skipper. For charitable services. Brian William Smith, lately Head of Operations, Securities and Investments Board. For services to Financial Regulation. Clifford John Smith. For services to the Newspaper Industry and to the community in Lincolnshire. Dennis Alfred Smith, lately Network Director, Southern Division, Central Office of Information. John Stanley Walter Smith, Head of Corporate Services Group, Her Majesty's Board of Customs and Excise. Neil Durden-Smith. For charitable services. Ian Nelson Sneddon, Chairman, Central Scotland Committee for the Employment of People with Disabilities. For services to the employment of disabled people. Kenneth Speakman, lately Pollution Inspector, Environment Agency. For services to Environmental Protection. Francis Richard Stanhope. For services to the Royal Air Force Association. Robert Russell Steedman, lately Member, Royal Fine Art Commission for Scotland. For services to the Built Environment in Scotland. Susan Elizabeth Stockley, Chairman, National Executive of the National Federation of Women's Institutes. For services to the Women's Institute Movement. John Howard Stoner, Regional General Manager, National Rivers Authority (Welsh Region). For services to the Environment in Wales.
== Selected publications == Books Identification and Application of Phenotypic and Molecular Markers for Abiotic Stress Tolerance in Soybean, Berhanu Amsalu Fenta, Belen Marquez Garcia, Christine H. Foyer, Karl J. Kunert, Magdeleen DuPlessis, Urte Schluter: 2011. INTECH Open Access Publisher: ISBN 978-953-307-721-5 A New Era in Plant Metabolism Research Reveals a Bright Future for Bio-fortification and Human Nutrition, Christine H Foyer, Dean Dellapenna, Dominique Van der Straeten: 2006 Plant Carbon-nitrogen Interactions from Rhizosphere to Plant, Caroline Bowsher, Christine H Foyer, Society for Experimental Biology: Oxford University Press: 2004. Molecular Physiology: Engineering Crops for Hostile Environments, Martin A Parry, Christine H Foyer, Brian Forde: Oxford University Press: 2000. ISBN Causes of Photooxidative Stress and Amelioration of Defense Systems in Plants, Christine H Foyer, Philip M Mullineaux: CRC Press: 1994. ISBN 978-0-8493-5443-4 Photosynthesis, Christine H Foyer, Kreiger Publishing Co.: 1991 ISBN 978-0-89464-506-8 Research articles Foyer, Christine H.; Halliwell, Barry (1976). "The presence of glutathione and glutathione reductase in chloroplasts: a proposed role in ascorbic acid metabolism". Planta. 133 (1): 21–25. doi:10.1007/BF00386001. PMID 24425174. S2CID 27896738.
Sources: en.wikipedia.org
=== Class I: Cys-based PTPs === Class I PTPs constitute the largest family. They contain the well-known classical receptor (a) and non-receptor PTPs (b), which are strictly tyrosine-specific, and the DSPs (c) which target Ser/Thr as well as Tyr and are the most diverse in terms of substrate specificity.
== Chemistry == The separation of the stereoisomers is one of the easier in organic chemistry and is described in the original patent. It involves "treatment of racemic methadone base with d-(+)-tartaric acid in an acetone/water mixture [which] precipitates almost solely the dextro-methadone levo-tartrate, and the more potent Levomethadone can easily be retrieved from the mother liquor in a high state of optical purity." There is now an asymmetric synthesis available to prepare both levomethadone (R-(−)-methadone) and dextromethadone (S-(+)-methadone).
==== Lieutenant of the Royal Victorian Order (LVO) ==== Hamish Blair, Senior Executive Officer, Scottish Office. Captain Robert Neil Blair, Royal Navy, Private Secretary to The Duke of York and to Princess Alexandra, the Honourable Lady Ogilvy. Laurence Albert Brown. For services to the Royal Collection. Donald Reeve Buttress, Surveyor of the Fabric, Westminster Abbey. Bernard Joseph Frahm, . For services to the Crown on Royal Visits to New Zealand. Commander Thomas Dixon Laidlaw, , Metropolitan Police. Leonora Mary, The Countess of Lichfield, Extra Lady in Waiting to The Princess Royal. Allan Arthur Percival, lately Press Secretary to The Prince of Wales. Alexander Hay Sutherland, Chief Publicity Officer, Scottish Office.
Larger doses do not appear to increase risks in this population. A broader retrospective study found that the rate of hyperkalemia in gender-diverse individuals is correlated with age, with those above 45 years old being more at risk. The finding suggests that patients below or at 45 years old without other conditions that affect potassium handling can be spared from routine monitoring.
A coffee bean is a seed from the Coffea plant and the source for coffee. This fruit is often referred to as a coffee cherry, but unlike the cherry, which usually contains a single pit, it most commonly contains two seeds with their flat sides together. The seeds are referred to as beans because of their appearance, though they are not true beans. A few coffee cherries, referred to as "peaberries" contain a single seed; they make up around 10% to 15% of all coffee beans. It is often claimed that peaberries are superior to normal beans, but there is little hard evidence to support this. Like Brazil nuts (a seed) and white rice, coffee beans consist mostly of endosperm. The two most economically important varieties of coffee plants are the arabica and the robusta, accounting for approximately 60% and 40% of the coffee produced worldwide, respectively. Arabica beans contain 0.8–1.4% caffeine and robusta beans contain 1.7–4.0% caffeine. As coffee is one of the world's most widely consumed beverages, coffee beans are a major cash crop and an important export product, accounting for over 50% of some developing nations' foreign exchange earnings. In 2023 the largest producer of coffee and coffee beans was Brazil. Other main exporters of coffee beans are Colombia, Vietnam, and Ethiopia.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
Reconstituted solutions are kept cold and used within the period stated on the label or certificate. Repeated warming and cooling cycles should be avoided because they encourage aggregation and gradual loss of potency.